Related Experiment Video

Updated: Aug 15, 2026

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

Management of hepatocellular carcinoma

Jordi Bruix1, Morris Sherman,

  • 1BCLC Group. Liver Unit. Hospital Clínic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain. bruix@ub.edu

Hepatology (Baltimore, Md.)
|October 27, 2005
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

Related Experiment Videos

Last Updated: Aug 15, 2026

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

Related Concept Videos

Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...

Articles linked to this work by shared authors, journal, and citation graph.

Clinical Trial: Early Nivolumab Addition to Regorafenib in Patients With Hepatocellular Carcinoma in Second-Line (The GOING Trial).

Alimentary pharmacology & therapeutics·2026

Utility of Serum Biomarkers in Addition to Ultrasound for Early Detection of Hepatocellular Carcinoma in High-Risk Patients: A Randomized Controlled Trial.

Gastroenterology·2026

BCLC strategy for prognosis prediction and treatment recommendations: The 2026 update.

Journal of hepatology·2025

Phase I trial of ADP-A2AFP TCR T-cell therapy in patients with advanced hepatocellular or gastric hepatoid carcinoma.

Journal of hepatology·2025

Disparities in access to systemic therapies for patients with hepatocellular carcinoma: an analysis from the International Liver Cancer Association.

The Lancet regional health. Europe·2025

Diagnostic performance of contrast-enhanced US in small liver nodules not conclusively characterized after MRI in cirrhotic patients.

European radiology·2025

Shear wave elastography demonstrates similar risk stratification performance to vibration-controlled transient elastography in FIB-4-based two-step algorithms for MASLD.

Hepatology (Baltimore, Md.)·2026

A First-in-Human study of AHB-137, an unconjugated antisense oligonucleotide, in healthy subjects and patients with chronic hepatitis B.

Hepatology (Baltimore, Md.)·2026

Hepatocyte hnRNPK preserves mitochondrial integrity to restrain liver injury and fibrosis.

Hepatology (Baltimore, Md.)·2026

Liver-on-a-Chip: Applications for clinical modeling of liver disease using microscale systems.

Hepatology (Baltimore, Md.)·2026

BEACON-HCC: Best evidence and north american consensus on treatment allocation for hepatocellular carcinoma.

Hepatology (Baltimore, Md.)·2026

With no lysine kinase 1 in hepatic stellate cells promotes mouse and human liver fibrosis through glycolytic triosephosphate isomerase 1.

Hepatology (Baltimore, Md.)·2026

Time to adjuvant chemotherapy after cytoreductive surgery and survival outcomes in epithelial ovarian cancer: a retrospective cohort study.

Frontiers in oncology·2026

Chitosan Nanoparticles for the Treatment of Ischemia-Reperfusion Injury: Mechanisms, Preclinical Evidence, Challenges, and Future Perspectives.

Journal of drug targeting·2026

Cost‑effectiveness of first‑line immunotherapy-based combination regimens for advanced renal cell carcinoma in China and the United States.

Human vaccines & immunotherapeutics·2026

CD7 CAR-T cells eliminate chronic myeloid leukemia stem cells specifically and effectively.

Hematology (Amsterdam, Netherlands)·2026

Impact of Immunotherapy Prescribing Restrictions on Time to Systemic Therapy and Outcomes in Metastatic Clear Cell Renal Carcinoma in Australia.

Asia-Pacific journal of clinical oncology·2026

Prognostic factors and outcomes associated with postmastectomy radiation therapy following neoadjuvant chemotherapy and mastectomy for breast cancer: A retrospective cohort study.

Medicine·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us